Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Taysha Gene Therapies Total Change in Assets/Liabilities 2020-2024 | TSHA

Taysha Gene Therapies total change in assets/liabilities from 2020 to 2024. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
  
Taysha Gene Therapies Annual Total Change in Assets/Liabilities
(Millions of US $)
2024 $-12
2023 $-18
2022 $19
2021 $29
2020 $0
2019 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.338B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.010B 6.96
Dr Reddy's Laboratories (RDY) India $11.261B 21.48
BridgeBio Pharma (BBIO) United States $6.894B 0.00
Bausch Health Cos (BHC) Canada $2.638B 1.91
Supernus Pharmaceuticals (SUPN) United States $1.805B 24.57
Amphastar Pharmaceuticals (AMPH) United States $1.553B 9.33
Personalis (PSNL) United States $0.323B 0.00
Assembly Biosciences (ASMB) United States $0.080B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00